drugset / Trial / NCT02382796
A Rollover Protocol of Dacomitinib For Patients In Japan
Open-labelTreatment
Summary
The purpose of this study to permit continued access to dacomitinib for patients who participated in other dacomitinib monotherapy treatment protocols in Japan and have the potential to derive clinical benefit without unacceptable toxicity from continued dacomitinib treatment.
Timeline
- Start
- 2015-07-10
- Primary completion
- 2019-05-30
- Completion
- 2019-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DACOMITINIB ANHYDROUS | Small molecule | 15 mg | Oral |
| Subject | DACOMITINIB ANHYDROUS | Small molecule | 30 mg | Oral |
| Subject | DACOMITINIB ANHYDROUS | Small molecule | 45 mg | Oral |